parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in neutrophil progenitors	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 120	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 11400

PTBP2 in dopamine neurons, braak+0.40 (p 0.287) → -0.37 (p 0.321)receipt 11410
PTBP2 in oligodendrocytes, braak-0.16 (p 0.685) → +0.50 (p 0.167)receipt 11409

receipt 11410: PTBP2 in dopamine neurons, braak

power: full sample +0.01 (p 0.962, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.01 (p 0.983, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.20 (p 0.434, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.15, sign flips 7; without severely affected donors +0.01 (p 0.962, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PTBP2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 11409: PTBP2 in oligodendrocytes, braak

power: full sample +0.27 (p 0.277, n 18), 95% CI -0.22 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.27 (p 0.273, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.22 (p 0.379, n 18). could be the mix.
skeptic: leave-one-out range +0.18 to +0.44, sign flips 0; without severely affected donors +0.27 (p 0.277, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PTBP2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts